CTCA In-Home Infusion Program Offers Patient-Centered Oncology Care
In Partnership With
Chevon Rariy, MD, discusses how the coronavirus disease 2019 pandemic has impacted the adoption of telehealth and the creation of the in-home infusion program, which allows cancer patients to continue their treatment at home while quarantining.
Chevon Rariy, MD, medical director of Endocrinology at Cancer Treatment Centers of America (CTCA) Chicago, and the Telehealth Program director for the CTCA, discusses how the coronoavirus disease 2019 (COVID-19) pandemic has impacted the adoption of telehealth and the creation of the in-home infusion program, which allows cancer patients to continue their treatment at home while quarantining.
According to Rariy, telehealth became vital during the COVID-19 pandemic, as social distancing was put into place. It allowed the transition of the modern health system to a virtual environment. This innovation, which was crucial during the pandemic, may help to redefine what cancer care looks like in the future.
Even slight delays in treatment may impact mortality or symptom management, according to Rariy. The in-home infusion program allows for patients to receive chemotherapy at home while using telehealth for follow-up appointments. This allows for the patient to maintain social distancing while also staying on their treatment schedule.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Enhancing Outcomes in Myeloma With CAR T Cells and Bispecific Antibodies
March 18th 2024March is Multiple Myeloma Awareness Month and experts like Amrita Krishnan, MD, and Adam D. Cohen, MD, explained the positive impact CAR T-cell therapies and bispecific antibodies have had in the space.
Read More
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More
